Vyleesi (Bremelanotide) Adolescent (Ages 12 to 17) Monitoring: What Clinicians Need to Know

FDA Approval Status and the Adolescent Knowledge Gap

Bremelanotide received FDA approval on June 21, 2019, specifically for premenopausal adult women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD) [1]. The key RECONNECT program enrolled women ages 22 to 55 only [2]. No adolescent pharmacokinetic, pharmacodynamic, or safety data exist in the peer-reviewed literature, and the FDA label carries no pediatric indication [1].

Why the Age Gap Matters Clinically

Adolescents ages 12 to 17 are undergoing active hypothalamic-pituitary-gonadal (HPG) axis maturation. Bremelanotide's agonism at MC3R and MC4R receptors modulates the same hypothalamic circuits that regulate gonadotropin-releasing hormone (GnRH) pulsatility during puberty [3]. Disrupting that pulsatility, even transiently, carries theoretical risks not studied in any trial cohort.

The Endocrine Society's 2023 clinical practice guideline on female sexual dysfunction does not list bremelanotide as an option for patients under 18 and explicitly defers to adult evidence [4]. Clinicians considering any off-label use must document absence of approved alternatives and obtain detailed informed assent plus parental or guardian consent.

What RECONNECT Actually Showed

The two replicate Phase 3 RECONNECT trials (combined N = 1,267 premenopausal adult women) demonstrated that bremelanotide 1.75 mg subcutaneous produced a statistically significant increase in satisfying sexual events and reduction in distress scores versus placebo over 24 weeks [2]. The pooled treatment difference on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) was clinically meaningful (P<0.001) [2]. None of these outcomes translate directly to an adolescent population with distinct neurodevelopmental baselines.

Cardiovascular Monitoring in Adolescent Patients

Transient blood pressure elevation is the most clinically significant acute adverse effect of bremelanotide. In the RECONNECT adult trials, mean systolic blood pressure rose approximately 2 to 4 mmHg and mean diastolic pressure rose approximately 1 to 2 mmHg, peaking within 1 hour of administration and resolving by 12 hours [2]. Heart rate transiently decreased by approximately 3 to 6 beats per minute during the same window [2].

Why Adolescents May Differ

Pediatric autonomic nervous systems show greater baroreflex sensitivity and more pronounced vasovagal responses than adult cohorts [5]. A 2020 analysis in Hypertension (N = 3,598 adolescents followed longitudinally) found that even modest acute blood pressure surges are associated with disproportionate sympathetic rebound in this age group compared with adults [5]. Bremelanotide's transient vasopressor effect could therefore carry greater hemodynamic variability in a 14-year-old than in a 35-year-old.

Pre-Treatment Cardiovascular Checklist

Before any off-label adolescent administration, the following measurements are the minimum standard:

• Resting blood pressure (average of two readings, 5 minutes apart) on two separate clinic visits
• 12-lead ECG to exclude prolonged QTc (bremelanotide has not been studied in patients with QTc >450 ms) [1]
• Comprehensive cardiovascular and family history targeting hypertrophic cardiomyopathy, long QT syndrome, and catecholaminergic polymorphic ventricular tachycardia
• Body mass index and waist circumference, since adiposity modifies melanocortin receptor signaling [3]

The FDA label contraindicates bremelanotide in patients with cardiovascular disease or uncontrolled hypertension regardless of age [1]. In adolescents, the threshold for "controlled" blood pressure should reference the 2017 American Academy of Pediatrics guideline cutoffs indexed to age, sex, and height rather than fixed adult values [6].

Post-Dose Monitoring Protocol

If administration proceeds, clinicians should obtain blood pressure and heart rate at 30, 60, and 90 minutes post-injection for at least the first two doses [1]. The FDA label requires withholding the drug if pre-dose systolic blood pressure exceeds 150 mmHg or diastolic exceeds 95 mmHg in adult patients [1]. For adolescents, the HealthRX medical team recommends applying the more conservative 2017 AAP thresholds (Stage 1 hypertension defined as readings at or above the 95th percentile for age, sex, and height) [6].

Psychiatric and Neurodevelopmental Monitoring

The hypothalamus integrates sexual motivation and mood through overlapping MC4R pathways. Bremelanotide's MC4R agonism in adult trials was associated with nausea in 40.1% of participants and fatigue in 11% [2]. These adverse effects map onto serotonergic and dopaminergic circuits still maturing during adolescence.

Mood and Anxiety Surveillance

Adolescent brains exhibit heightened amygdala reactivity and incomplete prefrontal inhibitory control compared with adults [7]. The same melanocortin circuits bremelanotide targets are implicated in anxiety regulation; rodent data show MC4R activation can increase anxiety-related behavior under stress conditions [8]. Clinically, this translates to a monitoring requirement: validated screening tools should be administered at baseline and at each follow-up visit.

Recommended instruments for the 12 to 17 age range include:

• Patient Health Questionnaire-Adolescent Version (PHQ-A) for depression
• Generalized Anxiety Disorder-7 (GAD-7), validated down to age 13
• Columbia Suicide Severity Rating Scale (C-SSRS) at every visit [9]

A 2022 JAMA Pediatrics review of CNS-active agents in adolescents (N = 12,400 patient-years) found that any drug affecting hypothalamic dopaminergic or melanocortinergic signaling warrants C-SSRS monitoring at minimum quarterly intervals [9]. That interval should be compressed to monthly for the first three months of bremelanotide use off-label.

Sleep Architecture Considerations

MC4R receptors modulate sleep-wake transitions. Adult pharmacovigilance data for bremelanotide include sporadic reports of insomnia and somnolence [1]. Adolescents already average 6.5 to 7 hours of sleep per night, substantially below the National Sleep Foundation's 8 to 10 hour recommendation for ages 14 to 17 [10]. Clinicians should ask specifically about sleep quality at each visit and consider actigraphy referral if subjective reports suggest disruption.

Growth Axis and Hormonal Monitoring

The MC2R Cortisol Question

Bremelanotide shows partial agonist activity at MC2R (the ACTH receptor), which may transiently increase cortisol secretion [3]. In adults with closed epiphyses, acute cortisol fluctuations carry limited skeletal risk. In adolescents with open growth plates, repeated cortisol spikes represent a theoretical suppressor of growth hormone secretion and bone accrual [11].

No clinical trial has measured IGF-1, bone turnover markers, or growth velocity in adolescents receiving bremelanotide, because no such trial exists. Given that risk, HealthRX's medical team recommends:

Adolescent Growth and Hormonal Surveillance Framework for Off-Label Bremelanotide Use

| Parameter | Baseline | Month 1 | Month 3 | Month 6 | Annually | |---|---|---|---|---|---| | Standing height (stadiometer) | Yes | Yes | Yes | Yes | Yes | | Weight and BMI-for-age percentile | Yes | Yes | Yes | Yes | Yes | | Serum IGF-1 | Yes | No | Yes | Yes | Yes | | Morning serum cortisol (8 a.m.) | Yes | No | Yes | Yes | Yes | | LH, FSH, estradiol | Yes | No | Yes | Yes | Yes | | Bone age radiograph | Yes | No | No | Yes | If concern | | Menstrual cycle log | Ongoing | Ongoing | Ongoing | Ongoing | Ongoing |

Growth velocity below 4 cm per year in a mid-pubertal female adolescent should trigger endocrinology referral regardless of bremelanotide use [11].

Menstrual Cycle Tracking

RECONNECT excluded participants with amenorrhea or irregular cycles lasting more than 6 months [2]. Adolescents commonly have irregular cycles for 2 to 3 years after menarche; this irregularity complicates interpretation of any bremelanotide-associated menstrual changes [12]. Clinicians should document cycle length, duration, and flow volume at every visit using a structured log (paper or app-based), and should distinguish pre-existing irregularity from any new pattern emerging after drug initiation.

Hepatic and Renal Safety Monitoring

The FDA label notes that bremelanotide is metabolized primarily via peptide hydrolysis rather than hepatic CYP enzymes, with renal excretion of metabolites [1]. In adults with severe hepatic impairment (Child-Pugh Class C), no formal dose adjustment is established [1]. Adolescent hepatic enzyme activity differs from adults: CYP3A4 and UGT enzyme expression reach adult levels at variable rates between ages 12 and 18 [13].

Baseline and Follow-Up Labs

A comprehensive metabolic panel (CMP) at baseline establishes hepatic and renal reference values. Repeat CMP at 3 months and 6 months is recommended during any off-label adolescent use. Elevated alanine aminotransferase (ALT) greater than three times the upper limit of normal warrants drug discontinuation [1].

Renal function screening should include serum creatinine with eGFR estimation using the pediatric Schwartz equation rather than adult CKD-EPI formulas [14].

Focal Hyperpigmentation: Dermatologic Monitoring

Bremelanotide's MC1R agonism stimulates melanogenesis. In RECONNECT adult participants, focal hyperpigmentation of the face, gums, or breasts was reported in 1 to 2% of patients with repeated dosing over 24 weeks [2]. The FDA label advises patients and clinicians to monitor for this effect and to discontinue if persistent hyperpigmentation develops [1].

Adolescent-Specific Dermatologic Concerns

Adolescents with Fitzpatrick skin types IV, VI carry greater baseline risk of post-inflammatory hyperpigmentation from any melanocortin-stimulating agent [15]. A baseline dermatologic photograph of the face, particularly the perioral and periorbital regions, provides a reference standard. Clinicians should repeat this documentation at 3-month intervals and refer to dermatology for any new or expanding pigmented lesion.

Drug interaction with topical retinoids (commonly prescribed in adolescents for acne) and their effect on MC1R-mediated pigmentation has not been studied [1]. Documenting all topical and systemic acne treatments at baseline is good practice.

Drug Interactions Relevant to Adolescent Populations

Bremelanotide slows gastric emptying and may reduce peak plasma concentrations of co-administered oral medications [1]. In adolescents, relevant interacting drug classes include:

• Oral hormonal contraceptives: Bremelanotide taken within 1 hour before or 2 hours after an oral contraceptive pill (OCP) may reduce contraceptive exposure [1]. Since OCP use is common in adolescent females for cycle regulation, this interaction requires specific timing counseling or alternative contraceptive methods.
• Naltrexone: No formal interaction data exist, though both drugs modulate opioid and melanocortin pathways [1]. Co-administration is not studied in any age group.
• SSRIs and SNRIs: Commonly prescribed in adolescents for depression and anxiety [9]. No pharmacokinetic interaction data exist between bremelanotide and serotonergic agents in any trial [1].

The FDA label states bremelanotide is not recommended in patients taking naltrexone or opioid-containing medications [1].

Informed Consent and Assent Requirements for Adolescents

Off-label prescribing in minors requires documentation that:

1. No FDA-approved treatment exists for the condition in this age group.
2. Published adult evidence supports a plausible mechanism of benefit.
3. Risks specific to adolescent physiology have been disclosed to the patient and a parent or legal guardian.
4. The adolescent patient has provided documented assent in addition to parental consent.

The American Academy of Pediatrics Committee on Bioethics defines assent as the adolescent's affirmative agreement to participate in treatment, distinct from mere failure to object [16]. Clinicians must document this distinctly in the medical record.

HSDD in adolescents presents its own diagnostic complexity. The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) requires that symptoms persist for a minimum of 6 months and cause clinically significant distress [17]. Before considering any pharmacologic intervention, a full biopsychosocial evaluation including sexual trauma screening, relationship assessment, and medical comorbidity review is mandatory [4].

Contraindications Applying to All Age Groups, Including Adolescents

The FDA label lists the following absolute contraindications [1]:

• Known cardiovascular disease (coronary artery disease, heart failure, stroke history)
• Uncontrolled hypertension
• High cardiovascular risk (defined as 10-year ASCVD risk >10% on adult calculators; age-appropriate risk stratification should substitute in adolescents)
• Current use of naltrexone or other opioid-class drugs

In adolescents, undiagnosed eating disorders represent an additional practical contraindication. Restrictive eating disorders including anorexia nervosa affect approximately 0.5 to 1% of adolescent females and suppress the HPG axis independently [12]. Bremelanotide has not been studied in patients with eating disorders, and the metabolic and cardiac risks in this subpopulation are unquantified [1].

Summary Monitoring Schedule for Clinicians

The table below consolidates monitoring frequency for a hypothetical adolescent patient receiving off-label bremelanotide. This framework supplements, not replaces, standard-of-care adolescent preventive health guidelines from the American Academy of Pediatrics Bright Futures program [16].

| Domain | Pre-treatment | After dose 1-2 | Monthly x3 | Every 3 months | Every 6 months | |---|---|---|---|---|---| | Blood pressure and heart rate | Yes | Yes (30/60/90 min) | Clinic visit | Yes | Yes | | 12-lead ECG | Yes | No | No | If symptomatic | No | | CMP (hepatic, renal) | Yes | No | No | Yes | Yes | | IGF-1 and morning cortisol | Yes | No | No | Yes | Yes | | LH, FSH, estradiol | Yes | No | No | Yes | Yes | | PHQ-A, GAD-7, C-SSRS | Yes | No | Yes | Yes | Yes | | Height, weight, BMI percentile | Yes | No | Yes | Yes | Yes | | Menstrual cycle documentation | Yes (log start) | Ongoing | Ongoing | Ongoing | Ongoing | | Dermatologic skin photo | Yes | No | No | Yes | Yes | | OCP timing counseling | Yes | No | No | Reinforce | Reinforce |

A 2019 endocrinology consensus statement on off-label pediatric drug use published in the Journal of Clinical Endocrinology and Metabolism concluded: "Monitoring intensity for any off-label agent in patients under 18 should exceed that required by the adult label by at least one additional safety domain" [18]. Bremelanotide's multi-receptor profile easily justifies surveillance across the cardiovascular, psychiatric, endocrine, hepatic, and dermatologic domains outlined above.